davamotecan pegadexamer (EP0057) / Ellipses Pharma |
NCT00753740: Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients. |
|
|
| Withdrawn | 2 | 0 | US | IT-101 (12mg/m2/dose), IT-101 (15mg/m2/dose), 5% Dextrose (Placebo) | NewLink Genetics Corporation | Cancer, Ovarian Cancer, Solid Tumor | 10/09 | 05/10 | | |
NCT01565421: Efficacy Study of Maintenance Therapy for Ovarian Cancer Patients |
|
|
| Withdrawn | 2 | 0 | US | IT-101, 5% Dextrose (Placebo) | NewLink Genetics Corporation | Cancer, Ovarian Cancer, Solid Tumor | 10/09 | 05/10 | | |
NCT01380769: A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer |
|
|
| Completed | 2 | 157 | RoW | CRLX101, NLG207, Best Supportive Care | NewLink Genetics Corporation | Non-Small Cell Lung Cancer | 02/13 | 10/14 | | |
|
|
NCT01612546: Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery |
|
|
| Completed | 2 | 10 | US | cyclodextrin-based polymer-camptothecin CRLX101, CRLX101, cyclodextrin-based polymer-camptothecin IT-101, IT-101, Laboratory biomarker analysis, Pharmacological studies | City of Hope Medical Center, National Cancer Institute (NCI) | Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Squamous Cell Carcinoma of the Esophagus, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer | 01/15 | 01/15 | | |
NCT01803269: Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer |
|
|
| Terminated | 2 | 29 | US | topotecan hydrochloride, hycamptamine, Hycamtin, SKF S-104864-A, TOPO, cyclodextrin-based polymer-camptothecin CRLX101, CRLX101, cyclodextrin-based polymer-camptothecin IT-101, IT-101 | University of Chicago, National Cancer Institute (NCI) | Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer | 03/16 | 03/16 | | |
NCT02187302: CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) |
|
|
| Completed | 2 | 115 | US, RoW | CRLX101, NLG207, Bevacizumab, Avastin, Standard of Care (Investigator Choice), sorafenib (Nexavar), sunitinib (Sutent), axitinib (Inlyta), pazopanib (Votrient), bevacizumab (Avastin),, everolimus (Afinitor), Other | NewLink Genetics Corporation | Metastatic Renal Cell Carcinoma | 07/16 | 01/17 | | |
|
|
NCT01652079: CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer |
|
|
| Completed | 2 | 63 | US | CRLX101 | Massachusetts General Hospital | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 03/18 | 03/18 | | |
|
|
|
|
|
NCT03531827: Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment |
|
|
| Terminated | 2 | 4 | US | enzalutamide, Xtandi, CRLX101, IT-101 | National Cancer Institute (NCI) | Metastatic Castration Resistant Prostate Cancer, Prostate Neoplasms | 05/21 | 06/21 | | |
| Completed | 2 | 34 | Europe, US | EP0057, Olaparib tablets, Lynparza | Ellipses Pharma | Ovarian Cancer | 02/23 | 05/23 | | |
NCT05411679: EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer |
|
|
| Withdrawn | 2 | 115 | RoW | EP0057, Olaparib tablets | Ellipses Pharma | Gastric Cancer, Small-cell Lung Cancer | 08/24 | 12/24 | | |
NCT00333502: Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors |
|
|
| Completed | 1b/2a | 62 | US | Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer, NLG207, IT-101 | NewLink Genetics Corporation | Cancer, Solid Tumor | 11/11 | 04/12 | | |
|
NCT02010567: Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer |
|
|
| Terminated | 1/2 | 32 | US | CRLX101, Capecitabine, Xeloda, Radiotherapy, Intensity Modulated Radiation Therapy, IMRT, Surgery, Resection, Surgical resection | UNC Lineberger Comprehensive Cancer Center, Cerulean Pharma Inc. | Rectal Cancer | 09/16 | 06/19 | | |
|
|
NCT02389985: A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
|
|
| Terminated | 1/2 | 30 | US | CRLX101, NLG207, Paclitaxel, Taxol | NewLink Genetics Corporation | Ovarian Cancer | 06/18 | 10/18 | | |
|
|
|
|